Evoke Pharma Inc. (NASDAQ:EVOK) has been given a consensus recommendation of “Hold” by the nine ratings firms that are presently covering the firm. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $5.60.
A number of equities research analysts have recently weighed in on the stock. Noble Financial lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, July 19th. Northland Securities lowered shares of Evoke Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, July 18th. Rodman & Renshaw restated a “buy” rating and issued a $27.00 price objective on shares of Evoke Pharma in a report on Monday, July 11th. Brean Capital reaffirmed a “buy” rating on shares of Evoke Pharma in a research note on Friday, July 8th. Finally, HC Wainwright set a $2.50 target price on shares of Evoke Pharma and gave the stock a “hold” rating in a research note on Tuesday, August 16th.
Evoke Pharma (NASDAQ:EVOK) opened at 1.92 on Monday. The company’s market capitalization is $23.71 million. The firm has a 50 day moving average of $2.02 and a 200-day moving average of $4.20. Evoke Pharma has a 1-year low of $1.52 and a 1-year high of $11.11.
Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings data on Monday, August 15th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. On average, equities research analysts anticipate that Evoke Pharma will post ($1.19) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Evoke Pharma by 5.0% in the second quarter. Vanguard Group Inc. now owns 62,381 shares of the specialty pharmaceutical company’s stock worth $427,000 after buying an additional 2,947 shares during the last quarter. State Treasurer State of Michigan bought a new position in shares of Evoke Pharma during the second quarter worth about $171,000. Finally, Bank of New York Mellon Corp increased its position in shares of Evoke Pharma by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 23,679 shares of the specialty pharmaceutical company’s stock worth $162,000 after buying an additional 464 shares during the last quarter. 8.19% of the stock is currently owned by institutional investors and hedge funds.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.